Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH
Abstract Bispecific antibodies (BsAbs), which simultaneously target two antigens and redirect immune T cells toward tumor cells, have emerged as one of the most promising immunotherapeutic strategies for multiple myeloma (MM). Based on previously reported clinical data, several BsAbs have been appro...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2026-04-01
|
| Serie: | Biomarker Research |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s40364-026-00912-4 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|